Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing CohortInterim Data from Atopic Dermatitis Trial ...

Two studies assessed the quality and accuracy of ChatGPT recommendations for atopic dermatitis based on their concordance with clinical guidelines.

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.

We are building out the ZORYVE product label with the expected approval of scalp and body psoriasis in the middle of 2025 as ...

The unique feline dermatological cases veterinary professionals can see at the clinic, plus how to approach them ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...